EMBC — Embecta Corp.

Summary of Embecta Corp. Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Revenue: Approximately $261 million, a 0.3% decline year-over-year (2% decline on an adjusted constant currency basis).
  • U.S. Revenue: $131 million, down 7.6% on an adjusted constant currency basis.
  • International Revenue: $130 million, up 8.4% reported (4.6% adjusted constant currency).
• Gross Profit: GAAP gross profit of $161.7 million (61.9% margin), compared to $151.7 million (60% margin) in the prior year.
• Operating Income: GAAP operating income of $83.3 million (31.9% margin), up from $28.7 million (11% margin) year-over-year.
• Net Income: GAAP net income of $44.1 million ($0.74 per diluted share), compared to zero in the prior year; adjusted net income of $42.3 million ($0.71 per share), up from $38.3 million ($0.65 per share).
• Free Cash Flow: Generated approximately $17 million; repaid $38 million in debt, reducing net leverage to 2.8 times.

2. Strategic Updates and Business Highlights

• Strategic Roadmap: Transitioning from the "stand-up" phase to the "seed growth" phase, focusing on portfolio expansion and becoming a broader medical supplies company.
• Brand Transition: Over 95% of U.S. and Canadian products have transitioned to the Embecta brand, with global transitions expected to be largely complete by the end of 2026.
• Medicare Part D: Secured additional exclusive contracts with Medicare Part D payers, enhancing access to products for diabetes patients.
• Product Development: Advancing market-appropriate pen needles and syringes, with manufacturing validation underway. Collaborating with over 30 pharmaceutical partners for co-packaging GLP-1 therapies.
• GLP-1 Strategy: Anticipating initial generic GLP-1 launches in 2026 across several markets, with ongoing discussions for additional partnerships.

3. Forward Guidance and Outlook

• Revenue Guidance: Reaffirmed guidance for 2026, expecting revenue to be flat to down 2% compared to 2025, leaning towards the lower end due to U.S. pricing pressures.
• Operating Margin and EPS: Adjusted operating margin guidance of 29-30% and adjusted EPS of $2.80 to $3.00, also leaning towards the lower end of these ranges.
• Debt Repayment: Expecting to repay approximately $150 million in debt and generate $180 million to $200 million in free cash flow for the year.

4. Bad News, Challenges, or Points of Concern

• U.S. Revenue Decline: Notable decline in U.S. revenue driven by lower pricing and volume, attributed to channel dynamics and customer mix.
• China Market Headwinds: Continued challenges in the Chinese market, with recovery expected to be more weighted towards the second half of the fiscal year.
• Pricing Pressures: Incremental pricing headwinds impacting revenue guidance, with expectations of lower revenue performance in the first half of 2026 compared to initial projections.

5. Notable Q&A Insights

• U.S. Business Dynamics: Management noted that the U.S. revenue decline was primarily due to a different customer and product mix, impacting pricing and volume.
• International Strength: Strong performance in EMEA and Latin America attributed to superior execution and new customer acquisitions.
• GLP-1 Market Confidence: Management remains optimistic about the GLP-1 opportunity despite the emergence of oral therapies, emphasizing the continued relevance of injectables and potential market expansion.
• Auto-Injector Project: Early phases of development with no specific timeline provided; management expressed confidence in R&D and market relationships for future growth.

This summary encapsulates the key takeaways from Embecta's Q1 2026 earnings call, highlighting both the company's achievements and the challenges it faces moving forward.